The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Beau M. Ances, MD, PhD
Project Title: Allzheimer Disease Neuroimaging Initiative 3 (ADNI3)
Date: [293]
Request ID: S1606
Aim 1: To discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research
Aim 2: To capture rates of decline on cognitive, global and functional tests and the rate of conversion to MCI or dementia due to AD.
Aim 3: Determine the longitudinal extent and rate of amyloid and tau deposition in PET Scans and longitudinal change of cerebral tau correlated and compared with other changes in cognition and biomarkers
Aim 4: Determine which clinical, cognitive and biomarker and imaging capture detection of treatment effects and measure cognitive decline for all groups with a focus on biomarkers and Tau.
Investigator: John C. Morris, MD
Project Title: Protocol 54861911ALZ2003: Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia
Date: [293]
Request ID: S1605
Aim 1: To deteremine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatement, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite, in amyloid positive subjects who are asymptomatic at risk for developing Alzheimer’s dementia.
Aim 2: To assess the overall safety and tolerability of JNJ-54861911 versus placebo.
Aim 3: To assess the effect of JNJ-54861911 compared with placebo on the Clinical Dementia Rating (CDR) scale, including progression from CDR 0 to CDR 0.5 or higher
Aim 4: To assess the maintenance of JNJ-54861911 effects on markers of AB processing in CSF and plasma compared with placebo.
Investigator: John C. Morris, MD
Project Title: Lilly LY3202626 (BACE Inhibitor) NAVIGATE-AD Trial
Date: [293]
Request ID: S1604
Aim 1: Safety/tolerability of LY3202626
Aim 2:
Aim 3:
Aim 4:
Investigator: Susan L Stark
Project Title: Participant Retention Study
Date: [293]
Request ID: S1603
Aim 1: Characterize the barriers and facilitators to longitudinal research in the KADRC
Aim 2: Characterize the reason for missing data in the KADRC longitudinal dataset
Aim 3:
Aim 4:
Investigator: Marie McNeely
Project Title: Development of a clinical tool to predict fall risk in Alzheimer disease
Date: [293]
Request ID: S1602
Aim 1: Identify predictors of falls in a large sample of individuals with Alzheimer disease.
Aim 2: Develop a new, simple clinical fall prediction tool that would be useful in routine care of individuals with Alzheimer disease.
Aim 3:
Aim 4:
Investigator: Lauren Richmond
Project Title: Training Long-Term Memory for Events
Date: [293]
Request ID: S1601
Aim 1: Identify implicit learning methods that facilitate normative event segmentation.
Aim 2: Test the effects of implicit learning on recall and recognition memory for events.
Aim 3: Assess the extent to which initial performance and benefit from training are sensitive to biomarkers of early stage AD.
Aim 4:
Investigator: Randall J. Bateman
Project Title: Stable isotope labeling & quantitative mass spectrometry imaging of amyloid-beta (Aβ) plaque deposition in human Alzheimer�s disease
Date: [293]
Request ID: S1510
Aim 1: Acquire in vivo stable isotope labeled images of Aβ plaques in human AD brain utilizing a validated NanoSIMS imaging protocol
Aim 2: Develop a computational mathematical framework that accurately quantifies 13C6-leucine-labeled protein deposition into plaques
Aim 3:
Aim 4:
Investigator: Tammie Benzinger
Project Title: An open label, multicenter study, evaluating the imaging characteristics of a follow-up 18F-AV-1451 scan in subjects who have had a prior 18F-AV-1451 scan
Date: [293]
Request ID: S1509
Aim 1: To assess the rate of change of tau deposition as measured by 18F-AV-1451 uptake over time.
Aim 2: To expand the 18F-AV-1451 safety database.
Aim 3:
Aim 4:
Investigator: Gregory Van Stavern, MD
Project Title: Ocular biomarkers in early and pre-clinical AD
Date: [293]
Request ID: S1508
Aim 1: Assess differences in OCT metrics between normals, pre-clinical AD and early AD subjects
Aim 2: Assess changes in retinal and optic nerve blood flow in pre-clinical and early AD
Aim 3: Measure subretinal protein degradation products using OCT and compare with brain ABeta
Aim 4:
Investigator: Palmer, Janice L.
Project Title: A pilot study of measurement of temperature and sleep in older adults with dementia
Date: [293]
Request ID: S1507
Aim 1: To evaluate the tolerability, feasibility and fidelity of a measurement protocol of temperature at wrist (using iButton)
Aim 2: To evaluate sleep parameters including time to onset of sleep, percent time awake and asleep during the night, number of awakenings per night, length of awakenings at night using wrist actigraphy (MotionWatch)
Aim 3: To evaluate the recruitment and retention of 10 adults age 65 and above (2 with no dementia [CDR=0] and 8 with mild to severe dementia [CDR=1 or above]) in a study of the measurement of temperature and sleep.
Aim 4: